Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of ASF 1057 cream 0.5% under long-term use in seborrhoeic dermatitis
2007-004649-14Phase 3Active
- Sponsor
- Astion Pharma
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ASF-1057 in seborrheic dermatitis (SD), sponsored by Astion Pharma. Primary endpoints: Incidence and severity of adverse events and adverse drug reactions and Patient discontinuations and reasons for discontinuations. Started Dec 2007; status: active.
02
Drugs
ASF-1057
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on 2007-004649-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004649-14.